Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Isoxazole derivative as mutated isocitrate dehydrogenase 1 inhibitor

A compound, hydrogen atom technology, applied in the field of isoxazole derivatives as mutant isocitrate dehydrogenase 1 inhibitor, can solve the problems of tumor properties and other issues

Active Publication Date: 2017-05-31
DAIICHI SANKYO CO LTD +1
View PDF12 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

From these reports, there is a possibility that the mutant IDH1 protein expressed in tumors may affect tumor properties by producing 2-HG through enzymatic activity different from that of wild-type IDH

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Isoxazole derivative as mutated isocitrate dehydrogenase 1 inhibitor
  • Isoxazole derivative as mutated isocitrate dehydrogenase 1 inhibitor
  • Isoxazole derivative as mutated isocitrate dehydrogenase 1 inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0973] [Example 1] (2E)-3-(1-{[5-(3-methyloxetane-3-yl)-3-(2,4,6-trichlorophenyl)-1 ,2- Azol-4-yl]carbonyl}-1H-indol-4-yl)prop-2-enoic acid

[0974] Formula 67

[0975]

[0976] [Step 1] 5-(3-methyloxetan-3-yl)-3-(2,4,6-trichlorophenyl)-1,2- Azole-4-carboxylic acid pentafluorophenyl ester

[0977] Under ice-cooling, to a dichloromethane solution (100ml) of the compound (10.2g) obtained in Reference Example X-11, were successively added dropwise N,N-bis(propan-2-yl)amine (7.6ml) and trifluoro Pentafluorophenyl acetate (7.3ml), and the mixture was stirred overnight at room temperature. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (n-hexane / dichloromethane) to obtain the title compound (11.4 g).

[0978] 1 H-NMR (CDCl 3 )δ: 1.92 (3H, s), 4.70 (2H, d, J = 6.7Hz), 5.21 (2H, d, J = 6.7Hz), 7.46 (2H, s).

[0979] [Step 2] (2E)-3-(1-{[5-(3-methyloxetan-3-yl)-3-(2,4,6-trichloropheny...

Embodiment 10

[0993] [Example 10] (2E)-3-(3-methyl-1-{[5-(1-methylcyclobutyl)-3-(2,4,6-trichlorophenyl)-1, 2- Azol-4-yl]carbonyl}-1H-indol-4-yl)prop-2-enoic acid

[0994] Formula 68

[0995]

[0996] [Step 1] 5-(1-methylcyclobutyl)-3-(2,4,6-trichlorophenyl)-1,2- Azole-4-carboxylic acid pentafluorophenyl ester

[0997] Using the compound (0.109 g) obtained in Reference Example X-14, the title compound (0.123 g) was obtained by the same method as in Step 1 of Example 1.

[0998] 1 H-NMR (CDCl 3 )δ: 1.72 (3H, s), 1.92-2.01 (1H, m), 2.14-2.30 (3H, m), 2.72-2.82 (2H, m), 7.44 (2H, s).

[0999] MS (m / z): 526 (M+H) + .

[1000] [Step 2] (2E)-3-(3-methyl-1-{[5-(1-methylcyclobutyl)-3-(2,4,6-trichlorophenyl)-1,2 - Azol-4-yl]carbonyl}-1H-indol-4-yl)prop-2-enoic acid tert-butyl ester

[1001] Using the compound obtained in Step 1 above (0.123 g) and the compound obtained in Reference Example E-8 (0.054 g), the title compound (0.103 g) was obtained by the same method as in Step 2 of Exa...

Embodiment 21

[1017] [Example 21] (2E)-3-(1-{[5-(2-fluoropropan-2-yl)-3-(2,4,6-trichlorophenyl)-1,2- Azol-4-yl]carbonyl}-3-methyl-1H-indol-4-yl)prop-2-enoic acid

[1018] Formula 69

[1019]

[1020] [Step 1] (2E)-3-(1-{[5-(2-fluoropropan-2-yl)-3-(2,4,6-trichlorophenyl)-1,2- Azol-4-yl]carbonyl}-3-methyl-1H-indol-4-yl)prop-2-enoic acid tert-butyl ester

[1021] To a solution of the compound (200 mg) obtained in Reference Example X-20 and N,N-dimethylformamide (10 µl) in dichloromethane (6 ml) was added oxalyl chloride (216 mg), and the mixture was stirred at room temperature for 30 minutes . The reaction solution was concentrated under reduced pressure to obtain acid chloride.

[1022] Under ice-cooling, to the compound obtained in Reference Example E-8 (218 mg), N,N-di(propan-2-yl)ethylamine (0.19 ml) and 4-dimethylaminopyridine (7.0 mg) To a dichloromethane (3 ml) solution was added dropwise a dichloromethane (3 ml) solution of the above acid chloride, and the mixture was stirred...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

It was discovered that a compound of general formula (I) that has an isoxazole skeleton has an excellent inhibitory activity on a mutated IDH1 protein, inhibits 2-HG production by the aforesaid protein and can effectively inhibit the proliferation of various tumors expressing the aforesaid protein. In general formula (I), R1, R2, R3, Y and Z are each as defined in claim 1.

Description

technical field [0001] The present invention relates to a compound having excellent inhibitory activity against mutant isocitrate dehydrogenase 1 (hereinafter also referred to as "IDH1") and a pharmaceutically acceptable salt thereof. Background technique [0002] Isocitrate dehydrogenases (IDHs: isocitrate dehydrogenases) are a group of enzymes that convert isocitrate into 2-oxoglutarate (α-ketoglutarate). This group of enzymes can be further subdivided into NAD+-dependent isocitrate dehydrogenases (EC 1.1.1.41) and NADP+-dependent isocitrate dehydrogenases (EC 1.1.1.42). [0003] IDH1 (isocitrate dehydrogenase 1 (NADP+), soluble) protein and IDH2 (isocitrate dehydrogenase 2 (NADP+), mitochondrial) protein are classified as NADP+-dependent isocitrate dehydrogenase (EC 1.1.1.42) enzymes. IDH1 gene mutations or IDH2 gene mutations are found in various cancers. Specific examples include glioma and glioblastoma, acute myeloid leukemia, myelodysplastic syndrome, myeloprolifer...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D413/06A61K31/422A61K31/437A61K31/4439A61K31/454A61K31/496A61K31/5377A61P35/00A61P35/02A61P43/00C07D413/14C07D471/04
CPCC07D413/14A61K31/422A61K31/437A61K31/4439A61K31/454A61K31/496A61K31/5377C07D413/06A61P35/00A61P35/02C07D471/04C07D413/04
Inventor 斋藤昭一伊藤雅夫藤泽哲则齐藤博直清冢洋平渡边秀昭松永大典神子岛佳子铃木彻也小川原阳子北林一生
Owner DAIICHI SANKYO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com